ALLN

Code: 208719-25MG D2-231

Biochem/physiol Actions

Primary TargetCalpain-1

Reversible: no

Product does not compete with ATP.

Target Ki: 190 nM, 220 nM, 150 nM, 500 pM, agai...


read more

Your Price
€314.70 EACH
€387.08 inc. VAT

Biochem/physiol Actions

Primary TargetCalpain-1

Reversible: no

Product does not compete with ATP.

Target Ki: 190 nM, 220 nM, 150 nM, 500 pM, against calpain I, calpain II, cathepsin B, and cathepsin L, respectively

Cell permeable: yes

General description

Inhibitor of calpain I (Ki = 190 nM), calpain II (Ki = 220 nM), cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM). Inhibits neutral cysteine proteases and proteasome (Ki = 6 µM). Protects against neuronal damage caused by hypoxia and ischemia. Inhibits apoptosis in thymocytes and metamyelocytes. Inhibits cell cycle progression at the G1/S border and metaphase/anaphase in CHO cells by inhibiting cyclin B degradation. Also prevents nitric oxide production by activated macrophages by interfering with transcription of the inducible nitric oxide synthase gene. Inhibits the proteolysis of IκBα and IκBβ by the ubiquitin-proteasome complex.

Cell-permeable inhibitor of calpain I (Ki = 190 nM), calpain II (Ki = 220 nM), cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM). Inhibits neutral cysteine proteases and the proteasome (Ki = 6 µM). Modulates the processing of the β-amyloid precursor protein (βAPP) to β-amyloid (Aβ). Protects against neuronal damage caused by hypoxia and ischemia. Inhibits apoptosis in thymocytes and metamyelocytes. Also inhibits reovirus-induced apoptosis in L929 cells. Inhibits the proteolysis of IκB-α and IκB-β by the ubiquitin-proteasome complex. Inhibits cell cycle progression at G1/S and metaphase/anaphase in CHO cells by inhibiting cyclin B degradation. Also prevents nitric oxide production by activated macrophages by interfering with transcription of the inducible nitric oxide synthase gene. A 10 mM (5 mg/1.30 ml) solution of ALLN (Cat. No. 208750) in DMSO is also available.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Debiasi, R.L., et al. 1999. J. Virol. 73, 695.Zhang, L., et al. 1999. J. Biol. Chem.274, 8966.Milligan, S.A., et al. 1996. Arch. Biochem. Biophys. 335, 388.Griscavage, J.M., et al. 1995. Biochem. Biophys. Res. Commun. 215, 721.Squier, M.K., et al. 1994. J. Cell Physiol.159, 229.Rami, J., and Kreiglstein, J. 1993. Brain Res.609, 67.Sherwood, S.W., et al. 1993. Proc. Natl. Acad. Sci.USA90, 3353.Vinitsky, A., et al. 1992. Biochemistry31, 9421.Sasaki, T., et al. 1990. J. Enzyme Inhib. 3, 195.

Packaging

5, 25 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Sequence

N-Acetyl-Leu-Leu-Nle-CHO

Warning

Toxicity: Standard Handling (A)

assay≥95% (HPLC)
colorwhite to off-white
formsolid
InChI keyFMYKJLXRRQTBOR-BZSNNMDCSA-N
InChI1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1
manufacturer/tradenameCalbiochem®
Quality Level100
shipped inambient
solubilityethanol: 5 mg/mL, DMSO: 10 mg/mL
storage conditionOK to freeze
storage temp.2-8°C
Cas Number110044-82-1
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN


GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.